| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/04/2004 | EP1385981A2 Antifungal compounds and methods of use |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385955A2 Cell adhesion proteins |
| 02/04/2004 | EP1385954A2 Proteins associated with cell growth, differentiation, and death |
| 02/04/2004 | EP1385945A1 Novel mutation |
| 02/04/2004 | EP1385883A2 Transmembrane proteins |
| 02/04/2004 | EP1385878A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 02/04/2004 | EP1385873A2 A ligand for enhancing oral and cns delivery of biological agents |
| 02/04/2004 | EP1385872A1 Inhibitors of receptor activator of nf-kappa b and uses thereof |
| 02/04/2004 | EP1385870A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |
| 02/04/2004 | EP1385856A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/04/2004 | EP1385820A1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof |
| 02/04/2004 | EP1385577A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 02/04/2004 | EP1385551A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| 02/04/2004 | EP1385550A2 Therapeutic method for inducing tolerance |
| 02/04/2004 | EP1385549A2 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 02/04/2004 | EP1385548A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/04/2004 | EP1385546A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| 02/04/2004 | EP1385534A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 02/04/2004 | EP1385533A1 Module of pd-1 interactions with its ligands |
| 02/04/2004 | EP1385531A2 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| 02/04/2004 | EP1385529A1 Treatment of refractory tumors using epothilone derivatives |
| 02/04/2004 | EP1385524A1 Pyrazolopyrimidines as therapeutic agents |
| 02/04/2004 | EP1385523A2 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| 02/04/2004 | EP1385522A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 02/04/2004 | EP1385516A1 The treatment of scarring and related conditions using ppar-gamma activators |
| 02/04/2004 | EP1385513A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 02/04/2004 | EP1385512A2 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 02/04/2004 | EP1385511A1 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis |
| 02/04/2004 | EP1385508A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/04/2004 | EP1385506A2 Acylated piperidine derivates as melanocortin-4 receptor agonists |
| 02/04/2004 | EP1385505A2 Acne treatment |
| 02/04/2004 | EP1385501A2 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| 02/04/2004 | EP1385499A1 Method for improving the well-being of poultry by in-ovo injection of carnitine |
| 02/04/2004 | EP1385498A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 02/04/2004 | EP1385496A2 Use of compositions for treating rosacea |
| 02/04/2004 | EP1385494A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs |
| 02/04/2004 | EP1385492A2 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 02/04/2004 | EP1385489A1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 02/04/2004 | EP1385476A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions |
| 02/04/2004 | EP1339416A4 Trace elements |
| 02/04/2004 | EP1296947B1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT |
| 02/04/2004 | EP1257304B1 Foam-forming wound dressing |
| 02/04/2004 | EP1196409B1 Respiratory syncytial virus replication inhibitors |
| 02/04/2004 | EP1107998B1 Method for the preparation of polyamide chains of precise length, their conjugates with proteins |
| 02/04/2004 | EP1107799B1 Method for labeling biopolymers using isotopes |
| 02/04/2004 | EP1030839B1 Use of alkylated iminosugars to treat multidrug resistance |
| 02/04/2004 | EP1007055B1 Use of amifostine |
| 02/04/2004 | EP0975954B1 Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
| 02/04/2004 | EP0938333B1 Method of enhancing the delivery of growth factors |
| 02/04/2004 | EP0684816B1 5-ht2 receptor antagonists for treating venous conditions |
| 02/04/2004 | CN1473265A Method for producing purified hematinic iron-saccharidic complex and product produced |
| 02/04/2004 | CN1473161A Pyrazole compounds as protein kinase inhibitors |
| 02/04/2004 | CN1473150A Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 02/04/2004 | CN1473055A Methods for enhancing efficacy of cytotoxic agents through use of HSP90 inhibitors |
| 02/04/2004 | CN1473052A PSGL-1 regulator |
| 02/04/2004 | CN1473050A Use of long pentraxin PTX3 for treatment of diseases caused by altered activation of growth factor FGF-2 |
| 02/04/2004 | CN1473047A Method for treating hypogonadism |
| 02/04/2004 | CN1473046A Improved treatment |
| 02/04/2004 | CN1473044A Inhalative solution formulation containing tiotropium salt |
| 02/04/2004 | CN1473042A Medical compositions |
| 02/04/2004 | CN1473040A Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity |
| 02/04/2004 | CN1473037A Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 02/04/2004 | CN1136919C Minoxidil compositions for external use |
| 02/03/2004 | US6686391 N-(mono-, di- trichlorophenyl)carbamates, thiocarbamates or dithiocarbamates; anticarcinogenic agents; viricides; safer than adriamycin on healthy cells; effective against cells of moncytic linage infected with hiv |
| 02/03/2004 | US6686388 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 02/03/2004 | US6686386 Combating photoinduced or chronological ageing of skin with retenoic acid receptor agonist |
| 02/03/2004 | US6686381 Compounds that antagonize neuropeptide y at the y5 receptor subtype represent an approach to the treatment of eating disorders such as obesity and hyperphagia |
| 02/03/2004 | US6686380 For tumors that have initially been unresponsive to taxane therapy and developed drug resistance |
| 02/03/2004 | US6686365 Pemetrexed, antioxidant of monothioglycerol, l-cysteine or thioglycolic acid and excipient; anticancer agents |
| 02/03/2004 | US6686340 Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells |
| 02/03/2004 | US6686337 Combination therapy comprising anti-diabetic and anticonvulsant agents |
| 02/03/2004 | US6686148 Methods for targeting RNA molecules |
| 02/03/2004 | US6685971 Oil homogenized with sterols; protective coating for stomach |
| 02/03/2004 | US6685964 Coated crystals |
| 02/03/2004 | US6685936 Administering lymphocytes |
| 02/03/2004 | US6685917 Treatment of mucositis |
| 02/03/2004 | US6685884 Retrieving a selected set of chemical compounds from an addressable chemical storage module with an automated robotic retriever; high throughput chemical screening oflow volume samples for new medicines, agrochemicals, or cosmetics |
| 02/03/2004 | CA2100655C Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis |
| 01/29/2004 | WO2004010146A1 Screening method and anti-tumor drug candidate obtained therefrom |
| 01/29/2004 | WO2004009816A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/29/2004 | WO2004009784A2 Novel inhibitors of kinases |
| 01/29/2004 | WO2004009762A2 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 01/29/2004 | WO2004009613A1 Anti-inflammatory or anti-allergic androstane complexes |
| 01/29/2004 | WO2004009601A1 Azaindole kinase inhibitors |
| 01/29/2004 | WO2004009549A2 Piperidines useful for the treatment of central nervous system disorders |
| 01/29/2004 | WO2004009542A2 Process for preparing certain pyrrolotriazine compounds |
| 01/29/2004 | WO2004009126A1 Targeted agents for nerve regeneration |
| 01/29/2004 | WO2004009119A1 Medicinal composition for treating arteriosclerosis |
| 01/29/2004 | WO2004009118A1 Preventive for the onset of diabetes |
| 01/29/2004 | WO2004009113A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | WO2004009101A1 Gel composition comprising sea salts |
| 01/29/2004 | WO2004009084A1 Methods of treating infection using antibiotics and glycogen phosphorylase inhibitors |
| 01/29/2004 | WO2004009075A1 Composition for solubilization of paclitaxel and preparation method thereof |
| 01/29/2004 | WO2004009073A1 P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 01/29/2004 | WO2004009072A2 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | WO2004009064A1 Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means |
| 01/29/2004 | WO2004009061A2 Bioavailability/bioefficacy enhaning activity of cuminum cyminum and extracts and fractions thereof |
| 01/29/2004 | WO2004009023A2 Novel inhibitors of ubiquitin isopeptidases |